Amgen Inc (AMGN)
Payables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Cost of revenue | US$ in thousands | 12,858,000 | 8,451,000 | 6,406,000 | 6,454,000 | 6,159,000 |
Payables | US$ in thousands | — | — | — | — | — |
Payables turnover | — | — | — | — | — |
December 31, 2024 calculation
Payables turnover = Cost of revenue ÷ Payables
= $12,858,000K ÷ $—K
= —
Based on the provided data for Amgen Inc, it appears that the payables turnover ratio is not available for the years 2020, 2021, 2022, 2023, and 2024. This lack of information hinders a comprehensive analysis of how efficiently the company is managing its accounts payable. Knowing the payables turnover ratio would have helped assess how quickly Amgen is paying off its suppliers and managing its working capital. Without this data, it is challenging to evaluate the company's liquidity and efficiency in managing its payable obligations.
Peer comparison
Dec 31, 2024
Company name
Symbol
Payables turnover
Amgen Inc
AMGN
—
ADMA Biologics Inc
ADMA
10.23
Bio-Techne Corp
TECH
25.82
Biogen Inc
BIIB
12.10
Gilead Sciences Inc
GILD
—
Halozyme Therapeutics Inc
HALO
—
Krystal Biotech Inc
KRYS
22.81
Moderna Inc
MRNA
—
Neurocrine Biosciences Inc
NBIX
—
Repligen Corporation
RGEN
—
Vericel Corp Ord
VCEL
—